肿瘤标志物检测联合^(18)F-FDG符合线路显像鉴别肺良恶性病变的临床价值  

Clinical Value of Assays of Multiple Serum Tumor Markers in Conjunction with ^(18)F-FDG SPECT for Discriminating Malignant from Benign Lung Disorders

作　　者：张春燕[1] 王玲珑[1] 屠丽萍[1] 俞月芳[1] 朱伟杰[1] 蔡傲[1] 高树兴[1] 

机构地区：[1]浙江省嘉兴市第一医院核医学科,314000

出　　处：《放射免疫学杂志》2006年第6期481-483,共3页Journal of Radioimmanology

摘　　要：目的探讨肿瘤标志物检测联合18F-FDG符合线路显像对鉴别肺良恶性病变的价值。方法对62例肺良恶性病变患者行18F-FDGSPECT肿瘤代谢显像及肿瘤标志物癌胚抗原(CEA)、糖类抗原50(CA50)、糖类抗原199(CA199)、糖类抗原242(CA242)检测,分别计算18F-FDG符合线路显像、肿瘤标志物CEA、CA50、CA199、CA242及18F-FDG符合线路显像与肿瘤标志物联合检测诊断肺恶性病变的灵敏度、特异性、准确性。结果18F-FDG符合线路显像对肺恶性病变诊断的灵敏度、特异性、准确性分别为85·7(30/35)、59·3(16/27)、74·2(46/62)。单项血清肿瘤标志物CEA、CA199、CA50、CA242检测对肺恶性病变诊断的灵敏度、特异性、准确性分别为22·9(8/35)、92·6(25/27)、59·7(33/62)、14·3(5/35)、100(27/27)、51·6(32/62)、34·3(12/35)、85·2(23/27)、56·5(35/62)、28·6(10/35)、85·2(23/27)、53·2(33/62),血清肿瘤标志物联检对肺恶性病变诊断的灵敏度、特异性、准确性分别为48.6(17/35)、81.5(22/27)、62.9(39/62),血清肿瘤标志物与FDG代谢显像联检对肺恶性病变诊断的灵敏度、特异性、准确性分别为88·6(31/35)、85·2(23/27)、87·1(54/62)。结论18F-FDG符合线路显像与肿瘤标志物联合检测诊断肺恶性病变的灵敏度、特异性、准确性均较高,对鉴别肺良恶性病变具有重要的临床应用价值。Objective To evaluate the clinical value of assays of multiple tumor markers in conjunction with ^18F-FDG SPECT for discriminating malignant from benign lung disorders. Methods A total of 62 patients with malignant and benign lung diseases underwet,^18F-FDG SPECT examinatinn and tests for sentm tumor markers CEA, CA50, CA199 and CA242, alone or combined. The sensilivity, specificity, accuracy of these tests were examined. Results The sensitivity, specificity accuracy of ^18F-FDG SPECT for the diagnosis of malignt, nt lung tumors were 85.7 （ 30/35 ）, 59.3 （16/27） and 74.2 （46/62） respectively, those of each of senlm CEA, CA199, CASO, CA242 levels in dlagnosing malignant lung tumors were 22.9 （ 8/35 ）, 92.6 （ 25/27 ）, 59.7 （ 33/62 ）, 14.3 （ 5/35）, 100（27/27）, 51.6（32/62）, 34.3（ 12/35）, 85.2（23/27）, 56.5（35/62）, 28.6（ 10/35）, 85.2（23/27） and 53.2（33/62） respectively, those of assays of multiple serum tumor markers for diagnosis of malignant lung tumors were 85.7 （ 30/35 ）, 85.2 （ 23/27 ） and 85.5 （53/62） respectively, those of assays of multiple tumor markers in conjunction with ^18F-FDG SPECT for discriminating malignant from benign lung nodules were 88.6 （31/35 ）, 85.2 （23/27） and 87.1 （54/62） respectively. Conclusion Assays of multiple serum tumor markers in conjuuction with ^18F-FDG SPECT for discriminating malignant from benign lung disorders can yield higher sensitivity, specialty and accuraey, making a significant contribution to clinical application.

关 键 词：肿瘤标志物 肺肿瘤 诊断 鉴别 体层摄影术 发射型计算机 单光子 脱氧葡萄糖 

分 类 号：R730.44[医药卫生—肿瘤]